<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37574270</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-9092</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of epidemiology</Title><ISOAbbreviation>J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Variant-specific Symptoms After COVID-19: A Hospital-based Study in Hiroshima.</ArticleTitle><Pagination><StartPage>238</StartPage><EndPage>246</EndPage><MedlinePgn>238-246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2188/jea.JE20230103</ELocationID><Abstract><AbstractText Label="BACKGROUND">Symptoms after novel coronavirus disease 2019 (COVID-19) recovery by severe acute respiratory syndrome coronavirus 2 strains are unspecified.</AbstractText><AbstractText Label="METHODS">This self-administered questionnaire-based study was conducted to investigate symptoms after COVID-19 recovery at one of the main hospitals for COVID-19 treatment in Hiroshima, Japan, from September 2020 to March 2022 for patients who visited follow-up consultations after COVID-19. Study subjects were divided into four groups (Wild-type, Alpha, Delta, and Omicron periods) according to COVID-19 onset date. Hierarchical cluster analysis was performed to determine symptom clusters and investigate risk factors for each symptom cluster using multivariate analysis.</AbstractText><AbstractText Label="RESULTS">Among 385 patients who enrolled in this study, 249 patients had any persistent symptoms at a median of 23.5 (interquartile range, 20-31) days after COVID-19 onset. Among patients with any persistent symptoms, symptom clusters including olfactory or taste disorders, respiratory symptoms, and cardiac symptoms were found. Respiratory symptoms were more frequent among patients infected in the Omicron period compared to the Wild-type period (adjusted odds ratio [AOR] 3.13; 95% confidence interval [CI], 1.31-7.48). Compared to patients who recovered from mild COVID-19, patients who needed oxygen or ventilation support suffered fewer post-COVID-19 respiratory symptoms (AOR 0.46; 95% CI, 0.22-0.97) but more post-COVID-19 cardiac symptoms among them (AOR 2.67; 95% CI, 1.26-5.65). Olfactory or taste disorders were fewer among patients infected in the Omicron period compared to the Wild-type period (AOR 0.14; 95% CI, 0.04-0.46).</AbstractText><AbstractText Label="CONCLUSION">This study revealed that symptoms after COVID-19 may vary depending on the infected strain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Kanon</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1476-7507</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Aya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8087-4319</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miwata</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitahara</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okimoto</LastName><ForeName>Mafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzaev</LastName><ForeName>Ulugbek</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hepatology, Scientific Research Institute of Virology, Ministry of Health of Uzbekistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurisu</LastName><ForeName>Akemi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1021-5243</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akita</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1056-3611</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ko</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6961-2000</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Kazuaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubo</LastName><ForeName>Tatsuhiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takafuta</LastName><ForeName>Toshiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Junko</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5669-4051</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Epidemiol</MedlineTA><NlmUniqueID>9607688</NlmUniqueID><ISSNLinking>0917-5040</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword><Keyword MajorTopicYN="N">variant</Keyword></KeywordList><CoiStatement>Conflicts of interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>7</Day><Hour>0</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>13</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37574270</ArticleId><ArticleId IdType="pmc">PMC10999520</ArticleId><ArticleId IdType="doi">10.2188/jea.JE20230103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Genomic epidemiology of SARS-CoV-2 with subsampling focused globally since pandemic start [homepage on the Internet]; c2022. Available from: https://www.gisaid.org/phylodynamics/global/nextstrain/.</Citation></Reference><Reference><Citation>Tracking SARS-CoV-2 variants [homepage on the Internet]; c2022. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>COVID-19 rapid guideline: managing the long-term effects of COVID-19 [homepage on the Internet]; c2021. Available from: https://www.nice.org.uk/guidance/ng188.</Citation></Reference><Reference><Citation>Coronavirus disease (COVID-19): Post COVID-19 condition [homepage on the Internet]; c2021. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.</Citation></Reference><Reference><Citation>Long COVID or Post-COVID Conditions [homepage on the Internet]; c2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>PHOSP-COVID Collaborative Group . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2013;775. 10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. 10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Management of Patients with COVID-19: Management of post COVID-19 conditon (version 2.0) [in Japanese] [homepage on the Internet]; c2022. Available from: https://www.mhlw.go.jp/content/000952747.pdf.</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Ogata T, Shibata T, et al. . Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant. Int J Environ Res Public Health. 2022;19:6330. 10.3390/ijerph19106330</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19106330</ArticleId><ArticleId IdType="pmc">PMC9140418</ArticleId><ArticleId IdType="pubmed">35627870</ArticleId></ArticleIdList></Reference><Reference><Citation>Del &#xc1;guila-Mej&#xed;a J, Wallmann R, Calvo-Montes J, Rodr&#xed;guez-Lozano J, Valle-Madrazo T, Aginagalde-Llorente A. Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. Emerg Infect Dis. 2022;28:1224&#x2013;1228. 10.3201/eid2806.220158</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2806.220158</ArticleId><ArticleId IdType="pmc">PMC9155885</ArticleId><ArticleId IdType="pubmed">35393009</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618&#x2013;1624. 10.1016/S0140-6736(22)00327-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii S, Sugiyama A, Ito N, et al. . The role of discrimination in the relation between COVID-19 sequelae, psychological distress, and work impairment in COVID-19 survivors. Sci Rep. 2022;12:22218. 10.1038/s41598-022-26332-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-26332-6</ArticleId><ArticleId IdType="pmc">PMC9782263</ArticleId><ArticleId IdType="pubmed">36564428</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama A, Miwata K, Kitahara Y, et al. . Long COVID occurrence in COVID-19 survivors. Sci Rep. 2022;12:6039. 10.1038/s41598-022-10051-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10051-z</ArticleId><ArticleId IdType="pmc">PMC8996498</ArticleId><ArticleId IdType="pubmed">35411017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fushimi M, Saito S, Shimizu T, Kudo Y, Seki M, Murata K. Prevalence of psychological distress, as measured by the Kessler 6 (K6), and related factors in Japanese employees. Community Ment Health J. 2012;48:328&#x2013;335. 10.1007/s10597-011-9416-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10597-011-9416-7</ArticleId><ArticleId IdType="pubmed">21547569</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujino Y, Uehara M, Izumi H, et al. . Development and validity of a work functioning impairment scale based on the Rasch model among Japanese workers. J Occup Health. 2015;57:521&#x2013;531. 10.1539/joh.15-0135-OA</Citation><ArticleIdList><ArticleId IdType="doi">10.1539/joh.15-0135-OA</ArticleId><ArticleId IdType="pmc">PMC6706181</ArticleId><ArticleId IdType="pubmed">26345178</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines [homepage on the Internet]; c2022. Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.</Citation></Reference><Reference><Citation>Ko K, Takahashi K, Nagashima S, et al. . Exercising the Sanger sequencing strategy for variants screening and full-length genome of SARS-CoV-2 virus during Alpha, Delta, and Omicron outbreaks in Hiroshima. Viruses. 2022;14:720. 10.3390/v14040720</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14040720</ArticleId><ArticleId IdType="pmc">PMC9030034</ArticleId><ArticleId IdType="pubmed">35458450</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714. 10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et al. . Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183:566&#x2013;580. 10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Imoto W, Yamada K, Kawai R, et al. . A cross-sectional, multicenter survey of the prevalence and risk factors for Long COVID. Sci Rep. 2022;12:22413. 10.1038/s41598-022-25398-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-25398-6</ArticleId><ArticleId IdType="pmc">PMC9793373</ArticleId><ArticleId IdType="pubmed">36575200</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of vaccines for COVID-19 [in Japanese] [homepage on the Internet]; c2023. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_yuukousei_anzensei.html.</Citation></Reference><Reference><Citation>Approved medications for COVID-19 (2023/04/01) [in Japanese] [homepage on the Internet]; c2023. Available from: https://www.mhlw.go.jp/content/10900000/001024113.pdf.</Citation></Reference><Reference><Citation>Alacevich C, Thalmann I, Nicodemo C, de Lusignan S, Petrou S. Depression and anxiety during and after episodes of COVID-19 in the community. Sci Rep. 2023;13:8257. 10.1038/s41598-023-33642-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-33642-w</ArticleId><ArticleId IdType="pmc">PMC10201488</ArticleId><ArticleId IdType="pubmed">37217539</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. 10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka S, Tsuzuki S, Suzuki M, et al. . Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J Infect Chemother. 2022;28:1546&#x2013;1551. 10.1016/j.jiac.2022.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.08.007</ArticleId><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="pubmed">35963600</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y, Otsuka Y, Honda H, et al. . Transitional changes in fatigue-related symptoms due to long COVID: a single-center retrospective observational study in Japan. Medicina (Kaunas). 2022;58:1393. 10.3390/medicina58101393</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58101393</ArticleId><ArticleId IdType="pmc">PMC9611667</ArticleId><ArticleId IdType="pubmed">36295554</ArticleId></ArticleIdList></Reference><Reference><Citation>Self-reported long COVID after infection with the Omicron variant in the UK: 6 May 2022 [homepage on the Internet]; c2022. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022#self-reported-long-covid-after-infection-with-the-omicron-variant-in-the-uk-data.</Citation></Reference><Reference><Citation>Hintschich CA, Niv MY, Hummel T. The taste of the pandemic-contemporary review on the current state of research on gustation in coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2022;12:210&#x2013;216. 10.1002/alr.22902</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22902</ArticleId><ArticleId IdType="pmc">PMC8653126</ArticleId><ArticleId IdType="pubmed">34704387</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Bilinska K, Von Bartheld CS. Chemosensory dysfunction in COVID-19: integration of genetic and epidemiological data points to D614G spike protein variant as a contributing factor. ACS Chem Neurosci. 2020;11:3180&#x2013;3184. 10.1021/acschemneuro.0c00596</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00596</ArticleId><ArticleId IdType="pmc">PMC7581292</ArticleId><ArticleId IdType="pubmed">32997488</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, Fischer WM, Gnanakaran S, et al. . Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812&#x2013;827.e19. 10.1016/j.cell.2020.06.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Bili&#x144;ska K, von Bartheld C. Why does the Omicron variant largely spare olfactory function? Implications for the pathogenesis of anosmia in coronavirus disease 2019. J Infect Dis. 2022;226:1304&#x2013;1308. 10.1093/infdis/jiac113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac113</ArticleId><ArticleId IdType="pmc">PMC9129133</ArticleId><ArticleId IdType="pubmed">35467743</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira IATM, et al. . Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2013;714. 10.1038/s41586-022-04474-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Enhancing response to Omicron SARS-CoV-2 variant [homepage on the Internet]; c2022. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.</Citation></Reference><Reference><Citation>Suzuki R, Yamasoba D, Kimura I, et al. . Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603:700&#x2013;705. 10.1038/s41586-022-04462-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Tirelli G, Meloni P, et al. . Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Omicron variant. Int Forum Allergy Rhinol. 2022;12:1273&#x2013;1281. 10.1002/alr.22995</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22995</ArticleId><ArticleId IdType="pmc">PMC9082058</ArticleId><ArticleId IdType="pubmed">35286777</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandal LT, MacDonald E, Veneti L, et al. . Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021;26:2101147. 10.2807/1560-7917.ES.2021.26.50.2101147</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.50.2101147</ArticleId><ArticleId IdType="pmc">PMC8728491</ArticleId><ArticleId IdType="pubmed">34915975</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudry RI, Brotto AR, Varughese RA, et al. . Persistent dyspnea after COVID-19 is not related to cardiopulmonary impairment; a cross-sectional study of persistently dyspneic COVID-19, non-dyspneic COVID-19 and controls. Front Physiol. 2022;13:917886. 10.3389/fphys.2022.917886</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2022.917886</ArticleId><ArticleId IdType="pmc">PMC9297912</ArticleId><ArticleId IdType="pubmed">35874528</ArticleId></ArticleIdList></Reference><Reference><Citation>Parshall MB, Schwartzstein RM, Adams L, et al. ; American Thoracic Society Committee on Dyspnea . An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435&#x2013;452. 10.1164/rccm.201111-2042ST</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201111-2042ST</ArticleId><ArticleId IdType="pmc">PMC5448624</ArticleId><ArticleId IdType="pubmed">22336677</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, et al. . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022. 10.1002/jmv.26368</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz-Corona C, Guti&#xe9;rrez-Canales LG, Ortiz-Ledesma C, et al. . Quality of life and persistence of COVID-19 symptoms 90 days after hospital discharge. J Int Med Res. 2022;50:3000605221110492. 10.1177/03000605221110492</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221110492</ArticleId><ArticleId IdType="pmc">PMC9284218</ArticleId><ArticleId IdType="pubmed">35822272</ArticleId></ArticleIdList></Reference><Reference><Citation>Report on the largest national survey of post COVID-19 condition (Press Release) [in Japanese] [homepage on the Internet]; c2022. Available from: https://www.keio.ac.jp/ja/press-releases/files/2022/6/2/220602-1.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>